<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> cells characteristically show strong expression of keratin 20 (K20) and lack expression of keratin 7 (K7) </plain></SENT>
<SENT sid="1" pm="."><plain>The biological significance of reduced K20 expression, however, is unclear </plain></SENT>
<SENT sid="2" pm="."><plain>381 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> with 148 corresponding <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> were evaluated for K20 and K7 expression by immunohistochemistry using a tissue microarray technique </plain></SENT>
<SENT sid="3" pm="."><plain>K20 immunoreactivity was assessed semiquantitatively as either negative, low (&lt;50% of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells) or high (â‰¥50% of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells) </plain></SENT>
<SENT sid="4" pm="."><plain>Progression-free and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survivals were determined using the Kaplan-Meier method </plain></SENT>
<SENT sid="5" pm="."><plain>Expression of K20 was observed in 348 out of 372 (94%) evaluable <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, with 135 (36%) cases showing low K20 and 213 (57%) cases high K20 expression, while 24 (6%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> completely lacked K20 immunoreactivity </plain></SENT>
<SENT sid="6" pm="."><plain>Reduced K20 expression (lack of staining or low expression) was significantly associated with poor differentiation, large <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size and mismatch repair deficiency, but did not significantly affect patients' outcome </plain></SENT>
<SENT sid="7" pm="."><plain>Immunoreactivity of K20 and K7 in metastatic tissues matched well with that of corresponding <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, with high concordance for lymph node (p&lt;0.001) and distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> (p&lt;0.001), respectively </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, our data illustrate the value of keratin subtyping in <z:mp ids='MP_0002038'>carcinoma</z:mp> of unknown primary (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CUP</z:e>) syndrome: K20 expression is common in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and the K20 high / K7 negative immunoprofile represents the predominant phenotype </plain></SENT>
<SENT sid="9" pm="."><plain>Reduced K20 expression may, however, lead to false-negative assessment of metastatic deposits if only small amounts of tissue are obtained (e.g. in needle biopsies), particularly in poorly differentiated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Reduced expression of K20 may be used to select <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> for microsatellite instability testing </plain></SENT>
</text></document>